Ultrasuoni focalizzati ad elevata intensità (HIFU) in pazienti con tumori solidi. Valutazione della fattibilità, della risposta locale e dei risultati clinici

Translated title of the contribution: High-intensity focused ultrasound (HIFU) in patients with solid malignancies: Evaluation of feasibility, local tumour response and clinical results

G. Orgera, L. Monfardini, P. Della Vigna, L. Zhang, G. Bonomo, P. Arnone, M. Padrenostro, F. Orsi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for ablation of solid tumours without damaging the surrounding structures. Materials and methods: A specific written informed consent was obtained from every patient before treatment. From September 2008 to April 2009, 22 patients with 29 lesions were treated: nine patients with liver and/or soft-tissue metastases from colorectal carcinoma (CRC), six with pancreatic solid lesions, three with liver and/or bone metastases from breast cancer, one with osteosarcoma, one with muscle metastasis from lung cancer, one with iliac metastasis from multiple myeloma and one with abdominal liposarcoma. The mean diameter of tumours was 4.2 cm. All patients were evaluated 1 day, 1 month and 3 months after HIFU treatment by multidetector computed tomography (MDCT), positron-emission tomography (PET)-CT and clinical evaluation. The treatment time and adverse events were recorded. Results: All patients had one treatment. Average treatment and sonication times were, respectively, 162.7 and 37.4 min. PET-CT or/and MDCT showed complete response in 11/13 liver metastases; all bone, soft-tissue and pancreatic lesions were palliated in symptoms, with complete response to PET-CT, MDCT or magnetic resonance imaging (MRI); the liposarcoma was almost completely ablated at MRI. Local oedema was observed in three patients. No other side effects were observed. All patients were discharged 1-3 days after treatment. Conclusions: According to our preliminary experience in a small number of patients, we conclude that HIFU ablation is a safe and feasible technique for locoregional treatment and is effective in pain control.

Original languageItalian
Pages (from-to)734-748
Number of pages15
JournalRadiologia Medica
Volume116
Issue number5
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Multidetector Computed Tomography
Neoplasm Metastasis
Neoplasms
High-Intensity Focused Ultrasound Ablation
Positron-Emission Tomography
Liposarcoma
Therapeutics
Liver
Magnetic Resonance Imaging
Bone and Bones
Sonication
Osteosarcoma
Informed Consent
Multiple Myeloma
Colorectal Neoplasms
Lung Neoplasms
Edema
Breast Neoplasms
Safety
Pain

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Ultrasuoni focalizzati ad elevata intensità (HIFU) in pazienti con tumori solidi. Valutazione della fattibilità, della risposta locale e dei risultati clinici. / Orgera, G.; Monfardini, L.; Della Vigna, P.; Zhang, L.; Bonomo, G.; Arnone, P.; Padrenostro, M.; Orsi, F.

In: Radiologia Medica, Vol. 116, No. 5, 08.2011, p. 734-748.

Research output: Contribution to journalArticle

@article{34099bc9c99e45d591c5c81d85cb8a32,
title = "Ultrasuoni focalizzati ad elevata intensit{\`a} (HIFU) in pazienti con tumori solidi. Valutazione della fattibilit{\`a}, della risposta locale e dei risultati clinici",
abstract = "Purpose: The purpose of this study was to evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for ablation of solid tumours without damaging the surrounding structures. Materials and methods: A specific written informed consent was obtained from every patient before treatment. From September 2008 to April 2009, 22 patients with 29 lesions were treated: nine patients with liver and/or soft-tissue metastases from colorectal carcinoma (CRC), six with pancreatic solid lesions, three with liver and/or bone metastases from breast cancer, one with osteosarcoma, one with muscle metastasis from lung cancer, one with iliac metastasis from multiple myeloma and one with abdominal liposarcoma. The mean diameter of tumours was 4.2 cm. All patients were evaluated 1 day, 1 month and 3 months after HIFU treatment by multidetector computed tomography (MDCT), positron-emission tomography (PET)-CT and clinical evaluation. The treatment time and adverse events were recorded. Results: All patients had one treatment. Average treatment and sonication times were, respectively, 162.7 and 37.4 min. PET-CT or/and MDCT showed complete response in 11/13 liver metastases; all bone, soft-tissue and pancreatic lesions were palliated in symptoms, with complete response to PET-CT, MDCT or magnetic resonance imaging (MRI); the liposarcoma was almost completely ablated at MRI. Local oedema was observed in three patients. No other side effects were observed. All patients were discharged 1-3 days after treatment. Conclusions: According to our preliminary experience in a small number of patients, we conclude that HIFU ablation is a safe and feasible technique for locoregional treatment and is effective in pain control.",
keywords = "Ablation, High-intensity focused ultrasound (HIFU), Solid tumours",
author = "G. Orgera and L. Monfardini and {Della Vigna}, P. and L. Zhang and G. Bonomo and P. Arnone and M. Padrenostro and F. Orsi",
year = "2011",
month = "8",
doi = "10.1007/s11547-011-0634-4",
language = "Italian",
volume = "116",
pages = "734--748",
journal = "Radiologia Medica",
issn = "0033-8362",
publisher = "Springer-Verlag Italia s.r.l.",
number = "5",

}

TY - JOUR

T1 - Ultrasuoni focalizzati ad elevata intensità (HIFU) in pazienti con tumori solidi. Valutazione della fattibilità, della risposta locale e dei risultati clinici

AU - Orgera, G.

AU - Monfardini, L.

AU - Della Vigna, P.

AU - Zhang, L.

AU - Bonomo, G.

AU - Arnone, P.

AU - Padrenostro, M.

AU - Orsi, F.

PY - 2011/8

Y1 - 2011/8

N2 - Purpose: The purpose of this study was to evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for ablation of solid tumours without damaging the surrounding structures. Materials and methods: A specific written informed consent was obtained from every patient before treatment. From September 2008 to April 2009, 22 patients with 29 lesions were treated: nine patients with liver and/or soft-tissue metastases from colorectal carcinoma (CRC), six with pancreatic solid lesions, three with liver and/or bone metastases from breast cancer, one with osteosarcoma, one with muscle metastasis from lung cancer, one with iliac metastasis from multiple myeloma and one with abdominal liposarcoma. The mean diameter of tumours was 4.2 cm. All patients were evaluated 1 day, 1 month and 3 months after HIFU treatment by multidetector computed tomography (MDCT), positron-emission tomography (PET)-CT and clinical evaluation. The treatment time and adverse events were recorded. Results: All patients had one treatment. Average treatment and sonication times were, respectively, 162.7 and 37.4 min. PET-CT or/and MDCT showed complete response in 11/13 liver metastases; all bone, soft-tissue and pancreatic lesions were palliated in symptoms, with complete response to PET-CT, MDCT or magnetic resonance imaging (MRI); the liposarcoma was almost completely ablated at MRI. Local oedema was observed in three patients. No other side effects were observed. All patients were discharged 1-3 days after treatment. Conclusions: According to our preliminary experience in a small number of patients, we conclude that HIFU ablation is a safe and feasible technique for locoregional treatment and is effective in pain control.

AB - Purpose: The purpose of this study was to evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for ablation of solid tumours without damaging the surrounding structures. Materials and methods: A specific written informed consent was obtained from every patient before treatment. From September 2008 to April 2009, 22 patients with 29 lesions were treated: nine patients with liver and/or soft-tissue metastases from colorectal carcinoma (CRC), six with pancreatic solid lesions, three with liver and/or bone metastases from breast cancer, one with osteosarcoma, one with muscle metastasis from lung cancer, one with iliac metastasis from multiple myeloma and one with abdominal liposarcoma. The mean diameter of tumours was 4.2 cm. All patients were evaluated 1 day, 1 month and 3 months after HIFU treatment by multidetector computed tomography (MDCT), positron-emission tomography (PET)-CT and clinical evaluation. The treatment time and adverse events were recorded. Results: All patients had one treatment. Average treatment and sonication times were, respectively, 162.7 and 37.4 min. PET-CT or/and MDCT showed complete response in 11/13 liver metastases; all bone, soft-tissue and pancreatic lesions were palliated in symptoms, with complete response to PET-CT, MDCT or magnetic resonance imaging (MRI); the liposarcoma was almost completely ablated at MRI. Local oedema was observed in three patients. No other side effects were observed. All patients were discharged 1-3 days after treatment. Conclusions: According to our preliminary experience in a small number of patients, we conclude that HIFU ablation is a safe and feasible technique for locoregional treatment and is effective in pain control.

KW - Ablation

KW - High-intensity focused ultrasound (HIFU)

KW - Solid tumours

UR - http://www.scopus.com/inward/record.url?scp=79961207642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961207642&partnerID=8YFLogxK

U2 - 10.1007/s11547-011-0634-4

DO - 10.1007/s11547-011-0634-4

M3 - Articolo

C2 - 21293939

AN - SCOPUS:79961207642

VL - 116

SP - 734

EP - 748

JO - Radiologia Medica

JF - Radiologia Medica

SN - 0033-8362

IS - 5

ER -